Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAH 243

Next Previous
X
Search
Drug Profile

BAH 243

Alternative Names: BAH-243; Lentiviral vector modified CD34+ hematopoietic stem cell therapy - Essen Biotech

Latest Information Update: 06 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Essen BioTech
  • Class Antianaemics; Gene therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Beta(A-T87Q) globin replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Sickle cell anaemia

Most Recent Events

  • 01 Aug 2024 Phase-I/II clinical trials in Sickle cell anaemia (In children, In adolescents, In adults, In the elderly) in China (IV) (NCT06399107)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top